TRAVERE THERAPEUTICS, INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-07-06.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2018-07-06
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $80.00K, a 94.97% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was -$203.00K, a 124.34% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-12-31 was $1.59M.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-09-30 was $834.00K.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2017 was $0.00.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was -$359.00K, a 114.80% decline from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $2.42M.
- TRAVERE THERAPEUTICS, INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-07-06 | |||
| 2016-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | -$123.00K derived: sum of 2 quarters · filed 2018-07-06 | -$359.00K 10-K · filed 2018-07-06 | |
| 2016-09-30 | -$203.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$439.00K 10-Q · filed 2016-11-04 | ||
| 2016-06-30 | -$236.00K 10-Q · filed 2016-08-05 | |||
| 2015-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $2.42M derived: sum of 2 quarters · filed 2018-07-06 | $2.42M 10-K · filed 2018-07-06 | |
| 2015-09-30 | $834.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $834.00K 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | $0.00 10-Q · filed 2016-08-05 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |